1932

Abstract

Diazeniumdiolates, compounds of structure R1R2NN(O)=NOR3, which have also been called NONOates, have proven useful for treating an increasing diversity of medical disorders in relevant animal models. Here, I review the chemical features that make them such excellent starting points for designing materials capable of targeting reliable and controllable fluxes of bioactive NO for in vitro and in vivo applications. This is followed by a consideration of recent proof-of-concept studies that underscore what I believe to be the substantial clinical promise of such materials. Examples covered include progress toward inhibiting restenosis after angioplasty, preparing thromboresistant medical devices, reversing vasospasm, and relieving pulmonary hypertension. Together with a very recent report describing the beneficial effects of diazeniumdiolate therapy in a patient with acute respiratory distress syndrome, the results of the animal experiments support the prediction that a broad selection of problems in clinical medicine can be solved by judiciously mining the enormous variety of possible R1R2NN(O)=NOR3 structures.

Loading

Article metrics loading...

/content/journals/10.1146/annurev.pharmtox.43.100901.135831
2003-04-01
2024-06-16
Loading full text...

Full text loading...

/content/journals/10.1146/annurev.pharmtox.43.100901.135831
Loading
/content/journals/10.1146/annurev.pharmtox.43.100901.135831
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error